-
At Patients as Partners EU: From Insight to Measurable, Scalable Impact—What’s Next for Patient Engagement
Key takeaways from Patients as Partners EU on measuring patient engagement, operationalizing patient experience data, scaling engagement programs, and translating patient insight into measurable outcomes.
-
The Growing Role of Patient Insight in Biotech Strategy and Decision-Making
As biotech organizations face growing operational complexity, patient insight is becoming a more important input for strategic and cross-functional decision-making.
-
The Missing Moment: When Patient Voice Enters Strategy Too Late
Patient insight often enters strategy after key decisions are already set, limiting its ability to shape evidence, positioning, and adoption. Introduced earlier, it informs the choices that drive differentiation, value…
-
How FDA Scrutiny and Patient Behavior Are Reshaping DTC’s Role in the US
DTC still drives awareness in the US, but it does not consistently support patient action on its own. FDA scrutiny and more complex patient journeys are shifting its role within…
-
RWE Reality Check: Closing the Gap Between Data and Decision-Making in Medical Affairs
Medical Affairs teams have more real-world data and more advanced analytics than ever, but decision-making is not getting easier. This article explores why more RWE and AI are not translating…
-
Medical Affairs ROI: Turning Scientific Engagement Into Measurable Impact
Interactions led by Medical Affairs, including scientific exchange with HCPs and engagement with patients and advocacy groups, can influence clinical decisions and patient behavior, but their impact is not always…
-
Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes
At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.
-
Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…
-
Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact
Late-stage clinical programs establish the evidence required for regulatory evaluation, but they do not guarantee adoption, access, or commercial performance. Translating that evidence into real-world impact requires patient-centered execution and…
-
How Peer Mentors Help Patients Start and Stay on Therapy in Rare Disease
In rare disease, a missing piece in starting and staying on therapy is often lived perspective. Patients and their care partners may begin rare disease treatment with no peer reference…
-
Turning Data into Dialogue: How Numbers Build Trust Between Patients and Clinicians
By Cheryl Lubbert, CEO of Reverba Global In healthcare, every word matters – but the way we communicate those words, and the numbers behind them, is changing. For patients to…
-
Closing the Gap: Why Patient Engagement Can’t Wait
Key Takeaways For all the progress in modern healthcare—from electronic records to AI-driven insights—a critical question remains: Why do so many people still feel unheard in their own care? Innovation…
